Are Syncom Formul. latest results good or bad?

Syncom Formulations (India) has reported its financial results for the quarter ending June 2025, showcasing a notable year-on-year growth in net sales, which reached Rs 265.78 crore, reflecting a growth rate of 64.23%. This indicates a robust near-term sales outlook for the company. However, when examining the quarter-on-quarter performance, net sales experienced a decline of 21.48% compared to the previous quarter, where sales were Rs 116.90 crore.
In terms of profitability, Syncom Formulations reported a profit after tax (PAT) of Rs 15.72 crore for the quarter, which represents a growth of 27.2% compared to the average PAT of Rs 12.36 crore over the preceding four quarters. Nonetheless, the quarter-on-quarter comparison shows a decline in consolidated net profit by 10.97% from Rs 15.75 crore in the previous quarter.

The operating profit margin, excluding other income, stood at 11.93%, indicating a slight change from the previous quarter's margin of 13.52%. Additionally, the company experienced fluctuations in interest expenses and exceptional items, with interest rising significantly by 108.33% from the previous quarter.

Overall, while Syncom Formulations has demonstrated strong year-on-year growth in sales and PAT, the quarter-on-quarter results reflect some challenges, including a decline in both net sales and net profit. Furthermore, the company saw an adjustment in its evaluation, highlighting the complexities of its market position despite the recent financial performance.